Having two copies of the ApoE4 gene is not just a risk factor for the development of Alzheimer’s, but is a likely cause of the disease, according to researchers in Spain.
Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh
To mark World Parkinson’s Day, former broadcaster Jeremy Paxman has delivered a list of recommendations for improving how the disease is managed in the UK to Prime Ministe
Researchers in the UK will soon start trialling blood tests that promise to diagnose dementia at clinics across the country in the hope of having them in rout
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for t
Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusio